Full Press Release Details
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity.
VKTX
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
Key Takeaway: Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
Price reaction · baseline $10.03 (2023-10-20 close) · 1 other VKTX headline(s) in the window, move may be shared
day 0 close · peak
+3.5%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+53%
120-day peak, hindsight
Typical move
13.6%
average across 5 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
VK2735
Phase 3 · Weight Loss